LETTER TO THE EDITOR

Oral candidiasis in non-severe COVID-19 patients: call for antibiotic stewardship

Dear Editor.

Bacterial/fungal coinfection is a suggested aetiological theory for the COVID-19-related oral manifestations that may trigger overprescribing of broadspectrum antibiotics for COVID-19 patients, especially for the ones who experience a longer course of the infection. Rigorous reporting of the clinical scenarios of fungal complications such as oropharyngeal candidiasis (OPC) could cause life-threatening candidemia that may help in understanding the on-going pandemic and the potential role of dentists in frontline teams^{1,2}. Therefore, we aim to describe a non-severe COVID-19 case with oral candidiasis according to the CARE guidelines³.

A 47-years-old female patient sought teleconsultation at our private dental clinic (Gharbia, Egypt) due to the appearance of painful white patches on the dorsal surface of the tongue and on the palate. Her medical history revealed that she used to take oral *levothyroxine* (Eltroxin) for mild hypothyroidism, and she was free of other underlying conditions, including cardiovascular disorders and diabetes mellitus.

Two weeks before the consultation, the patient suffered from a sore throat, generalised myalgia and fatigue with intermittent fever; therefore, she underwent a polymerase chain reaction (PCR) testing for SARS-COV-2 which yielded a positive result. During the following days, she experienced dry coughing without other respiratory symptoms, and her computed tomography (CT) scan was clear. Three days after the PCR testing, the patient started to experience anosmia and amblygeustia, which lasted until the end of her infection course. A few days later, burning sensation and mild tongue pain provoked by eating and speaking emerged.

Multivitamins and corticosteroids were prescribed by her physician since her infection was confirmed. While no improvement of her general health condition was observed, the physician added different types of antibiotics, including *azithromycin* (Zithromax), *linezolid* (Averozolid) and *ceftriaxone* (Xoraxon) to her treatment protocol. The prolonged use of antibiotics is believed to have led to worsening her oral manifestations.

On intraoral examination, multiple medium-sized pseudomembranous structures were detected with white plaques scattered over the dorsal surface of the tongue causing glossitis; and over the hard palate, thus, resembling OPC. A classic marker for this disease is the ability to easily wipe off the white plaques with gauze, leaving behind an erythematous surface which was also reported. The investigated patient consented to use her clinical and laboratory results for academic purposes while concealing her identifying personal data.

Heretofore, only one cohort of 53 hospitalised COVID-19 cases with OPC was reported where cardiovascular diseases and diabetes were the most common underlying conditions in addition to other risk factors such as old age, ICU admission, lymphocytopenia, broad-spectrum antibiotics and corticosteroids. Overall, broad-spectrum antibiotics usage was the most common risk factor as it occurred in 92.5% of the OPC cases².

A recent systematic review revealed an extensive prescription of antibiotics for COVID-19 cases (72%) while there was a lack of evidence on the association between SARS-COV-2 and respiratory bacterial/fungal coinfection. Our findings support the call to action made by Rawson et al. for urgent development of appropriate stewardship interventions specific for the COVID-19 pandemic⁴.

In conclusion, our case gives an account of the possibility of a potentially life-threatening opportunistic oral infection that had been caused by empirical broad-spectrum antibiotics prescription in a moderate COVID-19 case; and it also supports the involvement of dental practitioners among the interdisciplinary teams dealing with severely ill COVID-19 patients in ICUs⁵.

Conflict of Interest

The authors declare that there is no conflict of interest.

Abanoub Riad¹ , Akram Gad² , Barbora Hockova³ and Miloslav Klugar¹ ¹Czech National Centre for Evidence-Based Healthcare and Knowledge Translation (Cochrane Czech Republic, Czech EBHC: JBI Center of Excellence, Masaryk University GRADE Center), Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic; ²Department of Dental Biomaterials, Faculty of Dentistry, Tanta University, Tanta, Egypt and ³Department of Maxillofacial Surgery, F. D. Roosevelt University Hospital, Banska Bystrica, Slovak Republic email: abanoub.riad@med.muni.cz

Key words:

antimicrobial stewardship, candidiasis, COVID-19, oral manifestations, tongue

References

 Riad A, Klugar M, Krsek M. COVID-19 related oral manifestations, early disease features? Oral Dis 2020; https://doi.org/10.1111/odi.13516.

- Salehi M, Ahmadikia K, Mahmoudi S, Kalantari S, Jamalimoghadamsiahkali S, Izadi A et al. Oropharyngeal candidiasis in hospitalised COVID-19 patients from Iran: species identification and antifungal susceptibility pattern. Mycoses 2020;63:771–8. https://d oi.org/10.1111/myc.13137.
- 3. Gagnier JJ, Kienle G, Altman DG, Moher D, Sox H, Riley D *et al.* The CARE guidelines: consensus-based clinical case reporting guideline development. BMJ Case Rep. 2013;2013: https://doi.org/10.1136/bcr-2013-201554.
- Rawson TM, Moore LSP, Zhu N, Ranganathan N, Skolimowska K, Gilchrist M et al. Bacterial and fungal co-infection in individuals with coronavirus: a rapid review to support COVID-19 antimicrobial prescribing. Clin Infect Dis 2020; https://doi.org/10.1093/cid/ciaa530.
- 5. Dziedzic A, Wojtyczka R. The impact of coronavirus infectious disease 19 (COVID-19) on oral health. Oral Dis 2020; https://doi.org/10.1111/odi.13359.

466 Oral Surgery **15** (2022) 465-466.